176 related articles for article (PubMed ID: 17048354)
21. Hematological disorders in children with Down syndrome.
Triarico S; Trombatore G; Capozza MA; Romano A; Mastrangelo S; Attinà G; Maurizi P; Ruggiero A
Expert Rev Hematol; 2022 Feb; 15(2):127-135. PubMed ID: 35184659
[TBL] [Abstract][Full Text] [Related]
22. [GATA1-mutation associated leukemia in children with trisomy 21 mosaic].
Reinhardt D; Reinhardt K; Neuhoff C; Sander A; Klusmann JH; Pekrun A; Sauerbrey A; von Stackelberg A; Rössig C; Creutzig U; Kolenova A
Klin Padiatr; 2012 Apr; 224(3):153-5. PubMed ID: 22513796
[TBL] [Abstract][Full Text] [Related]
23. Hematological disturbances in Down syndrome: single centre experience of thirteen years and review of the literature.
Karakurt N; Uslu İ; Aygün C; Albayrak C
Turk J Pediatr; 2019; 61(5):664-670. PubMed ID: 32104997
[TBL] [Abstract][Full Text] [Related]
24. Analysis of GATA1 mutations and leukemogenesis in newborns with Down syndrome.
Queiroz LB; Lima BD; Mazzeu JF; Camargo R; Córdoba MS; Q Magalhães I; Martins-de-Sá C; Ferrari I
Genet Mol Res; 2013 Oct; 12(4):4630-8. PubMed ID: 24222239
[TBL] [Abstract][Full Text] [Related]
25. A 15q24 microdeletion in transient myeloproliferative disease (TMD) and acute megakaryoblastic leukaemia (AMKL) implicates PML and SUMO3 in the leukaemogenesis of TMD/AMKL.
Haemmerling S; Behnisch W; Doerks T; Korbel JO; Bork P; Moog U; Hentze S; Grasshoff U; Bonin M; Rieß O; Janssen JW; Jauch A; Bartram CR; Reinhardt D; Koch KA; Bandapalli OR; Kulozik AE
Br J Haematol; 2012 Apr; 157(2):180-7. PubMed ID: 22296450
[TBL] [Abstract][Full Text] [Related]
26. GATA1 mutations in Down syndrome: implications for biology and diagnosis of children with transient myeloproliferative disorder and acute megakaryoblastic leukemia.
Crispino JD
Pediatr Blood Cancer; 2005 Jan; 44(1):40-4. PubMed ID: 15390312
[TBL] [Abstract][Full Text] [Related]
27. Acute nonlymphocytic leukemia after transient myeloproliferative disorder in a patient with Down syndrome.
Barnett PL; Clark AC; Garson OM
Med Pediatr Oncol; 1990; 18(5):347-53. PubMed ID: 2142749
[TBL] [Abstract][Full Text] [Related]
28. Cytogenetic findings and clinical features in acute leukemia and transient myeloproliferative disorder in Down's syndrome.
Hayashi Y; Eguchi M; Sugita K; Nakazawa S; Sato T; Kojima S; Bessho F; Konishi S; Inaba T; Hanada R
Blood; 1988 Jul; 72(1):15-23. PubMed ID: 2968822
[TBL] [Abstract][Full Text] [Related]
29. Distinctive hematological abnormalities in East Asian neonates and children with Down syndrome.
Kim DW; Kim HR; Shin MG; Baek HJ; Kook H; Hwang TJ; Shin JH; Suh SP; Ryang DW
Int J Lab Hematol; 2011 Aug; 33(4):369-77. PubMed ID: 21692995
[TBL] [Abstract][Full Text] [Related]
30. Transient myeloproliferative disorder in neonates with and without Down syndrome: a tale of 2 syndromes.
Apollonsky N; Shende A; Ouansafi I; Brody J; Atlas M; Aygun B
J Pediatr Hematol Oncol; 2008 Nov; 30(11):860-4. PubMed ID: 18989165
[TBL] [Abstract][Full Text] [Related]
31. Transient myeloproliferative syndrome/transient acute myeloid leukemia in a newborn with Down syndrome: a case report and literature review.
D'Angelo G; Merlo P
Lab Hematol; 2003; 9(1):38-41. PubMed ID: 12661826
[TBL] [Abstract][Full Text] [Related]
32. Mutations of GATA1, FLT3, MLL-partial tandem duplication, NRAS, and RUNX1 genes are not found in a 7-year-old Down syndrome patient with acute myeloid leukemia (FAB-M2) having a good prognosis.
Kawamura M; Kaku H; Taketani T; Taki T; Shimada A; Hayashi Y
Cancer Genet Cytogenet; 2008 Jan; 180(1):74-8. PubMed ID: 18068539
[TBL] [Abstract][Full Text] [Related]
33. A neonate with a vesiculopustular rash.
Ansari DO; Lapping-Carr G; Alikhan M; Tsoukas ML; Stein SL; de Jong JL
Pediatr Ann; 2015 Jan; 44(1):e1-5. PubMed ID: 25621627
[TBL] [Abstract][Full Text] [Related]
34. Myeloid leukemia in Down syndrome.
Khan I; Malinge S; Crispino J
Crit Rev Oncog; 2011; 16(1-2):25-36. PubMed ID: 22150305
[TBL] [Abstract][Full Text] [Related]
35. Hematopoietic defects in the Ts1Cje mouse model of Down syndrome.
Carmichael CL; Majewski IJ; Alexander WS; Metcalf D; Hilton DJ; Hewitt CA; Scott HS
Blood; 2009 Feb; 113(9):1929-37. PubMed ID: 19109561
[TBL] [Abstract][Full Text] [Related]
36. Microarray transcript profiling distinguishes the transient from the acute type of megakaryoblastic leukaemia (M7) in Down's syndrome, revealing PRAME as a specific discriminating marker.
McElwaine S; Mulligan C; Groet J; Spinelli M; Rinaldi A; Denyer G; Mensah A; Cavani S; Baldo C; Dagna-Bricarelli F; Hann I; Basso G; Cotter FE; Nizetic D
Br J Haematol; 2004 Jun; 125(6):729-42. PubMed ID: 15180862
[TBL] [Abstract][Full Text] [Related]
37. Acute leukemias in children with Down syndrome.
Seewald L; Taub JW; Maloney KW; McCabe ER
Mol Genet Metab; 2012 Sep; 107(1-2):25-30. PubMed ID: 22867885
[TBL] [Abstract][Full Text] [Related]
38. Integrated differential transcriptome maps of Acute Megakaryoblastic Leukemia (AMKL) in children with or without Down Syndrome (DS).
Pelleri MC; Piovesan A; Caracausi M; Berardi AC; Vitale L; Strippoli P
BMC Med Genomics; 2014 Dec; 7():63. PubMed ID: 25476127
[TBL] [Abstract][Full Text] [Related]
39. Development of acute megakaryoblastic leukemia from a minor clone in a Down syndrome patient with clinically overt transient myeloproliferative disorder.
Xu G; Kato K; Toki T; Takahashi Y; Terui K; Ito E
J Pediatr Hematol Oncol; 2006 Oct; 28(10):696-8. PubMed ID: 17023834
[TBL] [Abstract][Full Text] [Related]
40. Hematological disorders in Down syndrome: ten-year experience at a Tertiary Care Centre in North India.
Awasthi A; Das R; Varma N; Ahluwalia J; Gupta A; Marwaha RK; Garewal G
Pediatr Hematol Oncol; 2005 Sep; 22(6):507-12. PubMed ID: 16169817
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
